Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
FLU VACCINES is a federal award for Division 1200 held by Glaxosmithkline LLC. Estimated value $526K ($-33,750.02 obligated). Current period of performance ends Nov 22, 2021. Last award drew 1 bidder. Place of performance: DURHAM NC.
Recompete timing
PublicCurrent PoP ended Nov 22, 2021 (1733 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15F06721F0002734?
15F06721F0002734 (FLU vaccines) is a Division 1200 award with a potential value of $526K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15F06721F0002734?
Division 1200 awarded 15F06721F0002734 to Glaxosmithkline LLC (potential $526K).
Who is the incumbent on 15F06721F0002734?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Nov 22, 2021.
When does Glaxosmithkline LLC’s 15F06721F0002734 come up for recompete?
SCOUT tracks a period-of-performance end of Nov 22, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.